RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
Sponsor:
Information provided by:
Repligen Corporation
ClinicalTrials.gov Identifier:
NCT00060515
First received: May 7, 2003
Last updated: August 4, 2005
Last verified: August 2005
  Purpose

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.


Condition Intervention Phase
Mitochondrial Diseases
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Resource links provided by NLM:


Further study details as provided by Repligen Corporation:

Estimated Enrollment: 12
  Eligibility

Ages Eligible for Study:   3 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Mitochondrial Disease

  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00060515     History of Changes
Other Study ID Numbers: RG2133-01
Study First Received: May 7, 2003
Last Updated: August 4, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Mitochondrial Diseases
Metabolic Diseases

ClinicalTrials.gov processed this record on April 15, 2014